Trial Profile

ECOSPOR: A RandomizEd, Double Blind, Placebo COntrolled, Parallel Group Study of SER 109 to Prevent Recurrent ClOstRidium Difficile Infection

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SER 109 (Primary)
Indications Clostridium difficile infections
Focus Therapeutic Use
Acronyms ECOSPOR
Sponsors Seres Therapeutics

Most Recent Events

07 Apr 2020 Results published in the Clinical Infectious Diseases.
08 Oct 2017 Results of this trial and another one (refer CTP: 700247159) assessing gut microbiome changes were presented at the IDWeek 2017
04 May 2017 According to Seres Therapeutics media release, data from this study was presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com